全文获取类型
收费全文 | 3400篇 |
免费 | 232篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 95篇 |
妇产科学 | 101篇 |
基础医学 | 422篇 |
口腔科学 | 99篇 |
临床医学 | 259篇 |
内科学 | 831篇 |
皮肤病学 | 58篇 |
神经病学 | 217篇 |
特种医学 | 138篇 |
外科学 | 683篇 |
综合类 | 20篇 |
预防医学 | 275篇 |
眼科学 | 69篇 |
药学 | 145篇 |
中国医学 | 7篇 |
肿瘤学 | 229篇 |
出版年
2023年 | 15篇 |
2022年 | 49篇 |
2021年 | 104篇 |
2020年 | 50篇 |
2019年 | 88篇 |
2018年 | 113篇 |
2017年 | 95篇 |
2016年 | 69篇 |
2015年 | 80篇 |
2014年 | 119篇 |
2013年 | 145篇 |
2012年 | 176篇 |
2011年 | 193篇 |
2010年 | 142篇 |
2009年 | 117篇 |
2008年 | 179篇 |
2007年 | 173篇 |
2006年 | 155篇 |
2005年 | 154篇 |
2004年 | 171篇 |
2003年 | 117篇 |
2002年 | 110篇 |
2001年 | 113篇 |
2000年 | 114篇 |
1999年 | 79篇 |
1998年 | 34篇 |
1997年 | 30篇 |
1996年 | 33篇 |
1995年 | 44篇 |
1994年 | 28篇 |
1993年 | 22篇 |
1992年 | 60篇 |
1991年 | 39篇 |
1990年 | 38篇 |
1989年 | 30篇 |
1988年 | 38篇 |
1987年 | 34篇 |
1986年 | 32篇 |
1985年 | 24篇 |
1984年 | 22篇 |
1983年 | 27篇 |
1982年 | 20篇 |
1981年 | 17篇 |
1980年 | 19篇 |
1979年 | 15篇 |
1978年 | 16篇 |
1975年 | 17篇 |
1974年 | 11篇 |
1968年 | 9篇 |
1967年 | 10篇 |
排序方式: 共有3660条查询结果,搜索用时 0 毫秒
101.
Evelio Rafael González Dalmau Carlos Cabal Mirabal Giselle Saurez Martínez Agustín Lage Dávila José Carlos Ugarte Suárez Ricardo Cabanas Armada Gretel Rodriguez Cruz Daniel Darias Zayas Martha Ríos Castillo Luis Valle Garrido Luis Quevedo Sotolongo Mercedes Monzón Fernández 《Pediatrics international》2014,56(1):43-46
102.
103.
A. Nast C. Smith P.I. Spuls G. Avila Valle Z. Bata-Csörgö H. Boonen E. De Jong I. Garcia-Doval P. Gisondi D. Kaur-Knudsen S. Mahil T. Mälkönen J.T. Maul S. Mburu U. Mrowietz K. Reich E. Remenyik K.M. Rønholt P.G. Sator M. Schmitt-Egenolf M. Sikora K. Strömer O. Sundnes D. Trigos G. Van Der Kraaij N. Yawalkar C. Dressler 《Journal of the European Academy of Dermatology and Venereology》2020,34(11):2461-2498
This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab. 相似文献
104.
Garel Juliette Blondiaux Eléonore Della Valle Valeria Guilbaud Lucie Khachab Farah Jouannic Jean-Marie Ducou le Pointe Hubert Garel Catherine 《Pediatric radiology》2020,50(4):575-582
A wide range of genitourinary pathologies can be diagnosed in utero, from a simple vesicoureteral reflux to a more complex disorder of sexual differentiation. The prognosis and neonatal management of these conditions differ significantly. Evaluation of the fetal perineal anatomy is paramount to making the right diagnosis. The aim of this pictorial essay is to show sonographers how to acquire a perineal midsagittal view in a male fetus, and to demonstrate how this specific view allows assessment of the urethra and penis, to differentiate various genitourinary pathologies.
相似文献105.
Francesco Poletto Luca Spiezia Chiara Simion Elena Campello Fabio Dalla Valle Daniela Tormene Giuseppe Camporese Paolo Simioni 《Viruses》2022,14(4)
Background: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but increases the risk of major bleeding in patients hospitalized for acute COVID-19 pneumonia. Objectives: To prospectively assess the incidence of objectively proven venous thromboembolism (VTE) and identify predisposing risk factors in a cohort of hospitalized patients with acute COVID-19 pneumonia undergoing prophylactic-dose heparin. Patients and methods: All consecutive patients admitted for acute COVID-19 pneumonia to the General Internal Medicine Unit of Padova University Hospital, Italy between November 2020 and April 2021, and undergoing prophylactic-dose heparin, were enrolled. Demographic and clinical characteristics and laboratory and radiological findings were recorded on admission. Cases were patients who developed VTE during their hospital stay. Univariable and multivariable logistic regression analyses were used to ascertain the risk factors associated with developing in-hospital VTE. Results: 208 patients (median age: 77 years; M/F 98/110) were included; 37 (18%) developed in-hospital VTE during a median follow-up of 10 days (IQR, 4–18). VTE patients were significantly younger (p = 0.004), more obese (p = 0.002), and had a lower Padua prediction score (p < 0.03) and reduced PaO2/FIO2 ratio (p < 0.03) vs. controls. Radiological findings of bilateral pulmonary infiltrates were significantly more frequent in VTE patients than controls (p = 0.003). Multivariable regression showed that obesity (1.75, 95% CI 1.02–3.36; p = 0.04) and bilateral pulmonary infiltrates on X-rays (2.39, 95% CI 1.22–5.69; p = 0.04) were correlated with increased risk of in-hospital VTE. Conclusions: Obesity and bilateral pulmonary infiltrates on imaging may help clinicians to identify patients admitted to medical wards for acute COVID-19 pneumonia at risk of developing VTE despite prophylactic-dose heparin. Further studies are needed to evaluate whether the administration of therapeutic/intermediate-dose heparin may help prevent VTE episodes without further increasing the bleeding risk. 相似文献
106.
Alejandro Leal Kathrin Huehne Finn Bauer Heinrich Sticht Philipp Berger Ueli Suter Bernal Morera Gerardo Del Valle James R. Lupski Arif Ekici Francesca Pasutto Sabine Endele Ramiro Barrantes Corinna Berghoff Martin Berghoff Bernhard Neundörfer Dieter Heuss Thomas Dorn Peter Young Lisa Santolin Thomas Uhlmann Michael Meisterernst Michael Werner Sereda Ruth Martha Stassart Gerd Meyer zu Horste Klaus-Armin Nave André Reis Bernd Rautenstrauss 《Neurogenetics》2009,10(4):275-287
107.
108.
Rodrigo G Taboada Rachel P Riechelmann Carine Mauro Milton Barros Richard A Hubner Mairad G McNamara Angela Lamarca Juan W Valle 《The oncologist》2022,27(2):97
BackgroundEverolimus-induced pneumonitis (EiP) has been poorly studied in patients with neuroendocrine neoplasms (NEN) outside clinical trials. The aim of this study was to evaluate the incidence, risk factors, and outcomes of EiP in patients with NENs using real-world data.MethodsRetrospective study of everolimus-treated patients with advanced NENs. Imaging reports were systematically reviewed for the presence of pneumonitis. Clinical features and treatment profiles for EiP were summarized. Overall survival (OS) was calculated from the initiation of everolimus to the date of death or last follow-up using the Kaplan-Meier method.ResultsA total of 122 patients were included. Median age at start of everolimus was 62 (19-86) years, 62% (76/122) were male, and half were from pancreatic origin (62, 51%). Twenty-eight patients (23%) developed EiP: 82% grade (G)1 or G2, 14% G3 and 4% G4. The median time to EiP was 3.6 (0.8-51) months. Primary tumor site, concurrent lung disease, smoking history, and prior therapies were not associated with the onset of EiP. Patients who developed EiP had longer time on everolimus treatment (median 18 months vs 6 months; P = .0018) and OS (77 months vs 52 months; P = .093). Everolimus-induced pneumonitis was a predictor of improved OS by multivariable analysis (HR 0.39, 95% CI 0.19-0.82; P = .013).ConclusionEverolimus-induced pneumonitis in the real-world clinical setting is present in one quarter of patients with NENs receiving everolimus and often occurs early. While risk factors for EiP were not identified, patients with EiP had improved survival. 相似文献
109.
Andrea Di Francesco Marny Fedrigo Donato Santovito Lucia Natarelli Chiara Castellani Fabio De Pascale Giuseppe Toscano Angela Fraiese Giuseppe Feltrin Elena Benazzi Angela Nocco Gaetano Thiene Marialuisa Valente Giorgio Valle Andreas Schober Gino Gerosa Annalisa Angelini 《The Journal of heart and lung transplantation》2018,37(11):1329-1340